General
Preferred name
FROVATRIPTAN
Synonyms
SB-209509AX ()
Frovatriptan (succinate hydrate) ()
FROVATRIPTAN SUCCINATE ()
(R)-Frovatriptan (succinate hydrate) ()
SB 209509 (succinate hydrate) ()
VML 251 (succinate hydrate) ()
SB 209509 Succinate,VML 251 Succinate ()
Frovatriptan succinate hydrate ()
Migard ()
Mylatrip ()
Frova ()
Allergo filmtabletten ()
VML-251 ()
SB-209509-AX ()
Frovelan ()
Miguard ()
SB 209509-AX ()
VML 251 ()
NSC-760422 ()
SB 209509 AX ()
P&D ID
PD009599
CAS
158930-09-7
158930-17-7
158747-02-5
Tags
available
drug
Approved by
FDA
First approval
2001
Drug Status
investigational
approved
Drug indication
Migraine
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Frovatriptan is a triptan (tryptamine-based) drug.
(GtoPdb)
DESCRIPTION
Frovatriptan is a selective agonist of the 5-HT1B and 5-HT1D (Kis = 2.51 and 3.98 nM, respectively).
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
62
Molecular Weight
243.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
1.34
TPSA
70.91
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
migraine headache
Target
HTR1A, HTR1B, HTR1D
5-HT Receptor
MOA
serotonin receptor agonist
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuronal Signaling
Source data
